Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
British clinical biotechnology company seeks for acquisition.
|Total value of the target||N/A|
|Expected target net rate of return after deducting all taxes and fees||N/A|
|Validity period of pending order||365|
Senior Associate, International Business Advisory
|Project highlights||Market capitalisation £ 19m|
The company is a UK based clinical biotechnology company dedicated to the development of new anti-infectives. Founded in the UK in 1997, it was listed on the London Stock Exchange (LSE) sub market alternative investment market (AIM) in 2017, with a market value of £ 19 million. In 2018, the first new drug for research (IND) was successfully launched in the United States, has obtained fast track qualification, and is starting the planned clinical plan. The pilot drug code named XF-XX has completed a clinical trial funded by the U.S. government. Different from traditional antibiotics, XF-XX shows excellent resistance to a specified bacterial in the laboratory - producing a series of potential low bacterial resistance, which can be used to prevent and treat methicillin resistant Staphylococcus aureus (MRSA) infection. Compared with traditional antibiotics, XF platform has the advantages of killing bacteria quickly, killing bacteria in any growth period and killing bacteria in staphylococcal bacterial biofilm. It is active against all Gram-positive bacteria tested so far and selected Gram-negative bacteria. No bacterial (MRSA) resistance was found. The company continued to strengthen its patent rights and granted XF biofilm patents in Canada in 2018, bringing the total number of patents granted by XF platform to 95.
Enquire for more information about our services, and how we can help solve challenges for your organizationContact Us